Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:30 2022-10-04 am EDT
332.75 CHF   +3.31%
12:51pGlobal Market Rally Pushes European Stocks Higher; Stoxx 600 Gains More Than 3%
MT
08:34aROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating
MD
08:18aROCHE HOLDINGS AG : JP Morgan remains Neutral
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Genentech - FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People with Previously Untreated Diffuse Large B-Cell Lymphoma

08/16/2022 | 06:43am EDT

South San Francisco - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Polivy in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).

The FDA is expected to make a decision on approval by April 2, 2023.

'The POLARIX study results suggest that Polivy plus R-CHP could transform the treatment of this aggressive malignancy, and we are working with the FDA to bring this combination to newly diagnosed DLBCL patients as soon as possible,' said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. 'We hope it will become the new standard of care for the first-line treatment of DLBCL, potentially reducing the need for subsequent treatments and limiting patient burden.'

DLBCL is an aggressive blood cancer. Although DLBCL often responds to initial treatment, it is not cured with the current standard of care in four out of 10 people. Most relapses occur within two years of starting treatment and the majority of those who require subsequent lines of therapy have poor outcomes.

The sBLA is based on results from the pivotal Phase III POLARIX trial, which is the first in two decades to show a clinically meaningful improvement in progression-free survival (PFS) compared to the current standard of care Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). The risk of disease progression, relapse or death was reduced by 27% with Polivy plus R-CHP compared with R-CHOP after a median follow-up of 28.2 months (hazard ratio [HR] 0.73; 95% confidence interval [CI]: 0.57-0.95; p

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about ROCHE HOLDING AG
12:51pGlobal Market Rally Pushes European Stocks Higher; Stoxx 600 Gains More Than 3%
MT
08:34aROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating
MD
08:18aROCHE HOLDINGS AG : JP Morgan remains Neutral
MD
04:19aSwitzerland's Roche Secures US FDA Nod for Breast Cancer Drug Enhertu's Companion Diagn..
MT
01:01aRoche receives FDA approval for first companion diagnostic to identify patients with HE..
GL
10/03Roche names Sause head of diagnostics arm
RE
10/03Roche Announces Management Changes
CI
10/03Roche Launches Its Next-Generation SARS-CoV-2 Rapid Antibody Test
CI
10/03Roche Announces Executive Changes
CI
09/30Xoma - EC Approved, VABYSMO for the Treatment of nAMD and DME
AQ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 63 990 M 65 317 M 65 317 M
Net income 2022 14 840 M 15 147 M 15 147 M
Net Debt 2022 11 189 M 11 421 M 11 421 M
P/E ratio 2022 17,8x
Yield 2022 2,90%
Capitalization 273 B 279 B 279 B
EV / Sales 2022 4,45x
EV / Sales 2023 4,30x
Nbr of Employees 100 920
Free-Float 89,0%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 332,75 CHF
Average target price 375,85 CHF
Spread / Average Target 13,0%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-15.04%267 122
JOHNSON & JOHNSON-3.19%429 082
ELI LILLY AND COMPANY16.41%305 529
PFIZER, INC.-24.71%247 729
ABBVIE INC.2.16%244 563
NOVO NORDISK A/S5.25%231 486